Harriet de Wit, Balázs Szigeti, Eline Haijen
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Psychedelics elevate neural activity, engage neural plasticity, and may relieve depression, anxiety, or addiction symptoms. Research focuses on neuron types and plasticity mechanisms in the prefrontal cortex.
Andrea Gomez
Overview of a multicenter trial compares psilocybin therapy to active control for demoralization in end-of-life adults. Trial focuses on treating depression, anxiety, and improving quality of life, spiritual well-being, and
Jessi Humphreys
Wellness and Psychedelics: Academic studies show psychedelics, in clinical settings with therapy, rapidly improve psychiatric conditions. Survey of 3,000 adults found significant improvements in mental health with psychedelic use.
Saundra Jain
Robin Carhart-Harris, Head of Centre for Psychedelic Research at Imperial College London, conducted pioneering clinical studies with psilocybin and other psychedelic drugs for over 40 years. He collaborates with Professor
5-MeO-DMT, a natural tryptamine, shows psychedelic effects by acting on serotonin receptors. Clinical trials suggest its potential for rapidly reducing depression symptoms, prompting further studies for depression treatment.
Johannes Reckweg
Elliot Cohen (Pillpack, Amazon) and Protik Basu (World Bank, UN, Helena) share insights on healthcare delivery, psychedelics industry, scaling challenges, and technology's role in patient care.
Andrew “Mo” Septimus, Protik Basu, Elliot Cohen
Roland Griffiths, Ph.D., from Johns Hopkins University, leads research on psilocybin's effects, including therapeutic studies for psychological distress, depression, addiction, and brain imaging for neural mechanisms.
Roland Griffiths
Carl Hart, Chair of Psychology at Columbia University, is a renowned neuropsychopharmacologist, author, and media personality known for challenging drug perceptions through research, books, and media appearances.
Carl Hart
Discussion between experts on pragmatic frameworks, demographic considerations, and evidence-based practices shaping psychedelic policy reform for diverse contexts, addressing regulatory challenges and fostering nuanced understanding.
Tatiana Quintana, Melissa Lavasani, Logan Davidson
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.